Lexicon Pharmaceuticals LXRX
NASDAQ LXRX
$1.86 +0.04 (+2.20%)
At close: Nov 10, 2026 · 4:00 PM EST

Lexicon Pharmaceuticals (LXRX) Cash from Restructuring (2022)

Updated

Analysis

Lexicon Pharmaceuticals (LXRX) Cash from Restructuring (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Lexicon Pharmaceuticals 860.99 Mn 220.29 Mn 11.17 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 1.50 Mn
Mar 31, 2022 1,500.00
API Access

Lexicon Pharmaceuticals Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=LXRX&period=max&api_key=YOUR_API_KEY